Published on 7 May 2024 on Zacks via Yahoo Finance
Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade
Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.